Video

Paul Jellinger from the University of Miami: ADA Provides New Insights Into Diabetes Treatment Methods

Author(s):

The annual meeting of the American Diabetes Association provided many studies looking at the condition from a variety of angles. What doctors did with those results when they went back to their practices was up to them.

%jwplayer%

The annual meeting of the American Diabetes Association provided many studies looking at the condition from a variety of angles. What doctors did with those results when they went back to their practices was up to them.

For Paul S. Jellinger, MD, from the University of Miami there were several key studies which caught his attention. One study in particular which he discussed at the conference involved the usage of once weekly exenatide. While not a new medication Jellinger said the study was important because it showed its benefits in helping to control a patient's blood glucose level over an extended period of time.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Viet Le, DMSc, PA-C | Credit: APAC
© 2025 MJH Life Sciences

All rights reserved.